Trials / Not Yet Recruiting
Not Yet RecruitingNCT06329947
A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (estimated)
- Sponsor
- Rui-hua Xu, MD, PhD · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To preliminarily evaluate whether there is a survival benefit of surufatinib combined with camrelizumab and mFOLFOX6 as the second-line treatment for advanced pancreatic cancer, and to explore the feasibility of second-line and post-line treatment for advanced pancreatic cancer
Detailed description
Second-line clinical study of surufatinib in combination with Caralizumab advanced pancreatic cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Surufatinib 250mg/d qd once daily | mFOLFOX6( Oxaliplatin + Leucovorin + fluorouracil) Oxaliplatin 85mg/m2 d1+CF 400mg/m2 d1+5-FU 400mg/m2d1 /2400mg/m2 continuous intravenous injection (civ) for 46h, The drug is administered every 14 days for a total of 8-12 cycles. |
Timeline
- Start date
- 2024-05-22
- Primary completion
- 2025-01-01
- Completion
- 2026-09-30
- First posted
- 2024-03-26
- Last updated
- 2024-05-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06329947. Inclusion in this directory is not an endorsement.